annual meeting program - American Society of Clinical Oncology

FRIDAY
Friday, June 4, 2010
Brd. 7 Preliminary safety data from a randomized trial of perioperative epirubicin,
cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients
(pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma.
(Abstract #4019)
A. F. Okines, R. Langley, F. H. Cafferty, S. P. Stenning, S. Falk, M. T. Seymour,
D. Smith, G. W. Middleton, F. Y. Coxon, D. Cunningham
Brd. 8 Randomized controlled trial to evaluate splenectomy in total gastrectomy for
proximal gastric carcinoma (JCOG0110): Analyses of operative morbidity,
operation time, and blood loss. (Abstract #4020)
T. Sano, M. Sasako, T. Shibata, S. Yamamoto, A. Tsuburaya, A. Nashimoto, S. Ito,
M. Kaji, H. Furukawa, N. Fukushima, Japan Clinical Oncology Group
Brd. 9 Perioperative chemotherapy with oxaliplatin/5-fluorouracil/leucovorin
(FOLFOX7) for locally advanced gastric cancer: Final results of a prospective
multicenter phase II study (BJSA-01) with 2 years follow-up. (Abstract #4021)
J. Ji, A. Wu, Z. Li, Y. Liu, R. Li, Z. Zhang, S. Wang, Y. Ye, F. Li
Brd. 10 Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery
for locoregionally advanced adenocarcinoma of the stomach,
gastroesophageal junction, and lower esophagus (GE adenocarcinoma).
(Abstract #4022)
U. Ronellenfitsch, M. Schwarzbach, R. Hofheinz, P. Kienle, P. Hohenberger,
K. Jensen, M. Kieser, T. E. Slanger, GE Adenocarcinoma Meta-analysis Group
Brd. 11 Comparison of the 2010 AJCC TNM staging system with a modified lymph
node ratio staging system in 7,233 gastric cancer patients. (Abstract #4023)
J. Wang, P. Dang, P. K. Pandalai, C. P. Raut, U. N. Maduekwe, S. S. Yoon
Brd. 12 Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC):
Results of a phase II/III randomized placebo-controlled trial. (Abstract #4024)
K. Okita, O. Matsui, H. Kumada, K. Tanaka, S. Kaneko, H. Moriwaki, N. Izumi,
T. Okusaka, Y. Ohashi, M. Makuuchi, Peretinoin Study Group
Brd. 13 A randomized phase II/III trial of three weekly cisplatin based transarterial
chemoembolization (TACE) versus embolization (TAE) alone for
hepatocellular cancer (HCC). (Abstract #4025)
T. Meyer, M. Roughton, D. Yu, N. Davies, E. Williams, S. P. Pereira,
D. Hochhauser, J. O’Beirne, D. Patch, A. K. Burroughs
Brd. 14 Study in Asia of the combination of transcatheter arterial chemoembolization
(TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial
(START): Second interim safety and efficacy analysis. (Abstract #4026)
Y. Chung, B. Kim, C. Chen, J. Wang, H. CHU, J. Yoon, K. Seetalarom, S. Bae,
Y. Chao, C. Li, T. Lee
Brd. 15 European multicenter evaluation of survival for patients with hepatocellular
carcinoma (HCC) treated by radioembolization with 90 y-labeled resin
microspheres. (Abstract #4027)
B. Sangro, L. Carpanese, R. Cianni, R. Golfieri, D. Gasparini, S. Ezzidin,
R. Hoffman, F. Fiore, on behalf of the European Network on Radioembolization
Using Y90 Microspheres (ENRY)
Brd. 16 The impact of antiviral therapy on the outcome of hepatitis B viral (HBV)related
hepatocellular carcinoma (HCC) detected in surveillance prorgram.
(Abstract #4028)
V. W. Wong, F. Mo, G. S. Liem, T. Mok, A. T. Chan, H. L. Chan, W. Yeo,
S. L. Chan
Brd. 17 Randomized phase II trial of S-1 and cisplatin versus gemcitabine and
cisplatin in advanced biliary tract adenocarcinoma. (Abstract #4029)
M. Kang, J. Lee, T. Kim, S. Lee, D. Park, D. Seo, M. Kim
Brd. 18 A randomized phase II study of TSU-68 in patients (pts) with hepatocellular
carcinoma (HCC) treated by transarterial chemoembolization (TACE).
(Abstract #4030)
Y. Arai, Y. Inaba, T. Yamamoto, F. Kanai, T. Aramaki, T. Tanaka, K. Yamakado,
M. Kudo, S. Kaneko, K. Imanaka
64